Copyright
©The Author(s) 2025.
World J Diabetes. Mar 15, 2025; 16(3): 101488
Published online Mar 15, 2025. doi: 10.4239/wjd.v16.i3.101488
Published online Mar 15, 2025. doi: 10.4239/wjd.v16.i3.101488
| Overall | Q1 (n = 2524) | Q2 (n = 2523) | Q3 (n = 2523) | Q4 (n = 2524) | P value |
TyG-WC | 1014.05 ± 160.17 | 815.26 ± 67.01 | 955.95 ± 31.22 | 1062.40 ± 31.75 | 1222.59 ± 85.99 | < 0.001 |
Age (years) | 62.80 ± 6.64 | 63.61 ± 7.09 | 63.26 ± 6.68 | 62.68 ± 6.54 | 61.66 ± 6.07 | < 0.001 |
Sex | < 0.001 | |||||
Male | 6206 (61.48) | 1323 (52.42) | 1527 (60.52) | 1617 (64.09) | 1739 (68.90) | |
Female | 3888 (38.52) | 1201 (47.58) | 996 (39.48) | 906 (35.91) | 785 (31.10) | |
Race | < 0.001 | |||||
White | 6302 (62.43) | 1075 (42.59) | 1445 (57.27) | 1778 (70.47) | 2004 (79.40) | |
Non-white | 3792 (37.57) | 1449 (57.41) | 1078 (42.73) | 745 (29.53) | 520 (20.60) | |
Education | < 0.001 | |||||
Less than high school graduate | 1492 (14.79) | 420 (16.66) | 415 (16.46) | 370 (14.67) | 287 (11.38) | |
High school grad (or GED) | 2662 (26.39) | 713 (28.28) | 640 (25.39) | 646 (25.61) | 663 (26.28) | |
Some college or technical school | 3311 (32.82) | 715 (28.36) | 799 (31.69) | 850 (33.70) | 947 (37.53) | |
College graduate or more | 2622 (25.99) | 673 (26.70) | 667 (26.46) | 656 (26.01) | 626 (24.81) | |
CVD history | 3556 (35.23) | 821 (32.53) | 872 (34.56) | 924 (36.62) | 939 (37.20) | 0.002 |
Duration of diabetes (years) | 10.79 ± 7.58 | 11.82 ± 8.06 | 11.11 ± 7.72 | 10.37 ± 7.21 | 9.86 ± 7.17 | < 0.001 |
Previous hypertension | 7609 (75.38) | 1895 (75.08) | 1896 (75.15) | 1868 (74.04) | 1950 (77.26) | 0.059 |
Previous hyperlipidemia | 7065 (69.99) | 1712 (67.83) | 1774 (70.31) | 1786 (70.79) | 1793 (71.04) | 0.050 |
Proteinuria | 2001 (19.83) | 432 (17.12) | 460 (18.23) | 519 (20.58) | 590 (23.38) | < 0.001 |
Heart failure | 484 (4.80) | 107 (4.24) | 85 (3.37) | 121 (4.80) | 171 (6.77) | < 0.001 |
Depression | 2394 (23.72) | 433 (17.16) | 519 (20.57) | 631 (25.03) | 811 (32.13) | < 0.001 |
Living alone | 2039 (20.20) | 516 (20.44) | 514 (20.38) | 497 (19.70) | 512 (20.29) | 0.908 |
Smoking | < 0.001 | |||||
Yes | 5886 (58.31) | 1257 (49.80) | 1449 (57.43) | 1532 (60.72) | 1648 (65.29) | |
No | 4208 (41.69) | 1267 (50.20) | 1074 (42.57) | 991 (39.28) | 876 (34.71) | |
Alcohol | 0.002 | |||||
Yes | 2414 (23.92) | 540 (21.39) | 629 (24.94) | 650 (25.78) | 595 (23.58) | |
No | 7676 (76.08) | 1984 (78.61) | 1893 (75.06) | 1871 (74.22) | 1928 (76.42) | |
BMI (kg/m2) | 32.21 ± 5.40 | 27.32 ± 3.80 | 30.80 ± 3.91 | 33.52 ± 4.07 | 37.20 ± 4.21 | < 0.001 |
SBP (mmHg) | 136.36 ± 17.10 | 136.82 ± 17.10 | 136.56 ± 17.39 | 136.27 ± 17.23 | 135.81 ± 16.67 | 0.156 |
DBP (mmHg) | 74.89 ± 10.66 | 73.40 ± 10.60 | 74.49 ± 10.41 | 75.37 ± 10.78 | 76.29 ± 10.64 | < 0.001 |
Heart rate, bpm | 72.66 ± 11.74 | 71.20 ± 11.25 | 72.08 ± 11.71 | 72.87 ± 11.73 | 74.50 ± 12.01 | < 0.001 |
FPG (mg/dL) | 175.21 ± 56.16 | 154.21 ± 53.15 | 168.08 ± 50.86 | 179.83 ± 52.30 | 198.70 ± 58.37 | < 0.001 |
HbA1c (%) | 8.30 ± 1.06 | 8.18 ± 1.05 | 8.25 ± 1.04 | 8.29 ± 1.04 | 8.47 ± 1.07 | < 0.001 |
TC (mg/dL) | 183.29 ± 41.85 | 176.93 ± 38.09 | 180.96 ± 40.52 | 183.75 ± 41.18 | 191.52 ± 45.89 | < 0.001 |
TG (mg/dL) | 190.26 ± 148.59 | 116.86 ± 69.17 | 162.72 ± 90.13 | 201.83 ± 119.22 | 279.62 ± 216.65 | < 0.001 |
VLDL-C (mg/dL) | 36.56 ± 24.38 | 23.21 ± 12.74 | 32.12 ± 16.35 | 39.43 ± 21.35 | 51.50 ± 32.60 | < 0.001 |
LDL-C (mg/dL) | 104.86 ± 33.89 | 105.98 ± 32.30 | 106.31 ± 34.13 | 104.31 ± 33.70 | 102.85 ± 35.27 | < 0.001 |
eGFR (mL/minute/1.73 m2) | 91.05 ± 27.18 | 91.55 ± 29.26 | 90.87 ± 29.19 | 89.95 ± 23.73 | 91.84 ± 26.11 | 0.074 |
WC (cm) | 106.74 ± 13.64 | 91.52 ± 7.73 | 102.48 ± 6.70 | 110.63 ± 7.10 | 122.32 ± 8.99 | < 0.001 |
WHtR | 0.63 ± 0.08 | 0.55 ± 0.05 | 0.61 ± 0.05 | 0.65 ± 0.05 | 0.71 ± 0.06 | < 0.001 |
Medications | ||||||
ARB/ACEI | 6992 (69.27) | 1674 (66.32) | 1736 (68.81) | 1752 (69.44) | 1830 (72.50) | < 0.001 |
CCB | 1929 (19.11) | 475 (18.82) | 493 (19.54) | 457 (18.11) | 504 (19.97) | 0.353 |
β-Blockers | 3041 (30.21) | 647 (25.71) | 715 (28.37) | 795 (31.64) | 884 (35.12) | < 0.001 |
Biguanides | 6455 (63.96) | 1542 (61.09) | 1638 (64.92) | 1618 (64.16) | 1657 (65.65) | 0.004 |
Thiazolidinediones | 2228 (22.07) | 513 (20.32) | 516 (20.45) | 572 (22.68) | 627 (24.84) | < 0.001 |
Sulfonylureas | 5401 (53.51) | 1370 (54.28) | 1335 (52.91) | 1342 (53.21) | 1354 (53.65) | 0.784 |
Insulins | 3522 (34.89) | 834 (33.04) | 878 (34.80) | 888 (35.20) | 922 (36.53) | 0.075 |
Statins | 6417 (63.81) | 1630 (64.91) | 1595 (63.37) | 1622 (64.57) | 1570 (62.38) | 0.221 |
Aspirin | 5497 (54.70) | 1302 (51.89) | 1343 (53.38) | 1432 (57.05) | 1420 (56.48) | < 0.001 |
Cholesterol absorption inhibitors | 205 (2.04) | 50 (1.99) | 55 (2.19) | 51 (2.03) | 49 (1.95) | 0.940 |
MACEs | 1791 (17.74) | 366 (14.50) | 426 (16.88) | 484 (19.18) | 515 (20.40) | < 0.001 |
Total mortality | 1914 (18.96) | 406 (16.09) | 447 (17.72) | 484 (19.18) | 577 (22.86) | < 0.001 |
- Citation: Liu MJ, Pei JY, Zeng C, Xing Y, Zhang YF, Tang PQ, Deng SM, Hu XQ. Triglyceride-glucose related indices as predictors for major adverse cardiovascular events and overall mortality in type-2 diabetes mellitus patients. World J Diabetes 2025; 16(3): 101488
- URL: https://www.wjgnet.com/1948-9358/full/v16/i3/101488.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i3.101488